Tiziana Reports Positive Phase 2 PET Imaging Data for Foralumab in Multiple System Atrophy

summarizeSummary

Tiziana Life Sciences announced initial positive Phase 2 clinical trial results for intranasal foralumab in Multiple System Atrophy (MSA), showing a significant reduction in brain inflammation in the first two patients.

check_boxKey Events

• Positive Phase 2 Data in MSA

  Initial quantitative PET imaging results from the first two patients in the Phase 2 trial for intranasal foralumab in Multiple System Atrophy (MSA) showed a marked reduction in brain inflammation.

• Significant Reduction in Inflammation

  Investigators observed up to approximately 35% reduction in standardized uptake value (SUV) and 24% reduction in standardized uptake value ratio (SUVR) in affected brain regions.

• Third Indication with Positive Biomarker Data

  This marks the third indication where intranasal foralumab has demonstrated a reduction in inflammation on PET scans, following previous positive results in multiple sclerosis and Alzheimer's disease.

• Addresses High Unmet Need

  MSA is a rare, progressive neurodegenerative disorder with no approved disease-modifying treatments, highlighting the potential impact of these early findings.

auto_awesomeAnalysis

This positive clinical update is highly important for Tiziana Life Sciences, especially following the 'going concern' warning disclosed in its recent 20-F filing. The initial Phase 2 data, though from only two patients, provides quantitative evidence of reduced brain inflammation in Multiple System Atrophy, a severe condition with no current treatments. Demonstrating biological activity in a third indication strengthens the potential of intranasal foralumab and could be crucial for attracting future investment or partnerships needed to address the company's financial runway.